Bayer to spend almost $700M on German sites for hemophilia drugs

03/13/2014 | PharmaTimes (U.K.) · Reuters

Bayer plans to spend nearly $700 million to expand production capacity at its Wuppertal and Leverkusen sites in Germany, where it plans to manufacture its two experimental hemophilia A drugs. Both drugs, BAY 81-8973 and BAY 94-9027, are in late-stage trials. Bayer said the investment would create about 500 new jobs at the two sites by 2020.

View Full Article in:

PharmaTimes (U.K.) · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN